HeartFlow is the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology(HeartFlow® FFRCT), and plaque information (Plaque analysis) based on Coronary computed tomography angiography (CCTA).

HeartFlow, a company that is revolutionizing precision heart care, has recently announced the closure of a Series F funding round worth $215 million. The funding was led by Bain Capital Life Sciences and saw participation from new investor Janus Henderson Investors, as well as existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, and Wellington Management.

The funding will help HeartFlow meet the growing demand for its commercial products, support its clinical evidence, and advance its comprehensive product portfolio that enables physicians to diagnose coronary artery disease and guide their treatment decisions. The oversubscription of HeartFlow’s Series F funding round is a strong validation of its technology, team, and opportunity, said HeartFlow CEO, John Farquhar. (HeartFlow)

HeartFlow has experienced remarkable growth and has been recognized by the recent ACC/AHA Chest Pain Guidelines for its coronary computed tomography angiography (CCTA) and FFRCT. Its FFRCT technology is covered by over 98% of commercial payers and 100% of Medicare.

With the recent FDA clearance of new products, HeartFlow is the only company that provides non-invasive coronary artery anatomy, physiology, and plaque information based on CCTA. This comprehensive approach enables physicians to gain a better understanding of a patient’s CAD and predict the risk of a heart attack.

The company’s product pipeline is expected to continue to advance the company’s position as a precision diagnostics leader. The company’s future product launches will enable it to further support physicians in their commitment to improving cardiovascular patient outcomes. It has been published in more than 500 peer-reviewed publications showcasing the value of anatomy, physiology, and plaque.

The company’s technology has aided in the diagnosis of heart disease for over 180,000 patients.

Related Story:  AI Predicts Cardiac Attacks, Analyzes Urine, And Hernia Surgery Outcomes